Scynexis SCYX
NASDAQ SCYX
$4.91 -0.24 (-4.66%)
At close: Sep 9, 2026 · 4:00 PM EDT

Scynexis (SCYX) Total Non-Current Liabilities (2013 - 2026)

Scynexis' (SCYX) quarterly Total Non-Current Liabilities came in at $7.2 million in Q2 2026, down 45.66% on a YoY basis from $13.3 million in Q2 2025, and down 58.44% quarter-over-quarter from $17.4 million in Q1 2026.

Analysis

Scynexis (SCYX) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends

Scynexis (SCYX) has reported Total Non-Current Liabilities for 14 consecutive years, with $7.2 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Total Non-Current Liabilities fell 45.66% year-over-year to $7.2 million; the trailing twelve-month figure through Jun 2026 stood at $7.2 million (down 45.66% YoY), and the FY2025 full-year result was $7.4 million, down 73.06% from the prior year.
  • Total Non-Current Liabilities retreated to $7.2 million in Q2 2026 per SCYX's latest filing, from $17.4 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $68.9 million in Q2 2022 and bottomed at $7.2 million in Q2 2026.
  • Historically, Total Non-Current Liabilities has averaged $33.8 million across 5 years, with a median of $29.5 million in 2023.
  • The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities jumped 166.56% in 2022, then sank 73.06% in 2025.
  • Over 5 years, Total Non-Current Liabilities stood at $65.9 million in 2022, then slumped by 48.96% to $33.6 million in 2023, then declined by 18.08% to $27.6 million in 2024, then tumbled by 73.06% to $7.4 million in 2025, then slipped by 2.5% to $7.2 million in 2026.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $7.2 million, $17.4 million, and $7.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn 81.11 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn 36.04 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn 5.92 Bn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn 7.74 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn 40.00 Mn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn 3.92 Bn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn 4.20 Bn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn 12.42 Bn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn 378.37 Mn
10 Scynexis 58.41 Mn -56.29 Mn - 7.24 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 7.24 Mn
Mar 31, 2026 17.42 Mn
Dec 31, 2025 7.43 Mn
Sep 30, 2025 11.10 Mn
Jun 30, 2025 13.32 Mn
Mar 31, 2025 12.28 Mn
Dec 31, 2024 27.57 Mn
Sep 30, 2024 29.30 Mn
Jun 30, 2024 29.40 Mn
Mar 31, 2024 31.95 Mn
Dec 31, 2023 33.65 Mn
Sep 30, 2023 31.96 Mn
Jun 30, 2023 29.68 Mn
Mar 31, 2023 59.89 Mn
Dec 31, 2022 65.93 Mn
Sep 30, 2022 67.35 Mn
Jun 30, 2022 68.90 Mn
Mar 31, 2022 64.64 Mn
Dec 31, 2021 60.52 Mn
Sep 30, 2021 56.97 Mn